Objective: Adjuvant chemotherapy (AC) in resected pancreatic adenocarcinoma (PDAC) can lead to doubled 5-year survival rates. To date, the impact of institutional volume on “rate of” and “time to” adjuvant chemotherapy (AC) for pancreaticoduodenectomy (PD), partial/distal pancreatectoemy (PP) and total pancreatectomy (TP) for PDAC has not been investigated. Methods: NCDB was queried for resected PDAC between 2010 and -2012. Patients with M1 and T1 N0 with negative margins were excluded. After correcting for confounders (age, sex, size, margins, T-,N- stage, comorbidities and hospital stay), the odds ratio (OR) of receiving and delay past 90 days of AC following PD, PP, TP for each volume quartile institution was compared to highest quartile. Factors were analyzed by multivariable regression analysis for the entire cohort and each procedure. Results: 8797 patients met inclusion criteria, 56.8% received AC with 9.5% receiving it after 90 days. AC rates for Quartile (Q) 1, Q2, Q3, and Q4 were as follows: 55.7%, 60.4%, 57.6%, 59.6%, 58.6% (p=0.016). After correcting for confounders, compared to the top quartile, Q1 and Q2 had lower odds of receiving AC. For all quartiles and procedures, time to discharge was associated with omission or delay of AC (p=0.003). Laparoscopic compared to open approach for PP in the highest 2 quartiles had higher odds of receiving AC. Only Q4 showed higher rates and lower odds of delay of AC for laparoscopic PD. Conclusion: PAC patients who have pancreatectomy at lower-volume institutions are less likely to receive AC. These data support centralization of treatment, including surgery independent of approach, for patients with PAC.